IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
IMUNON announced that enrollment in its pivotal Phase 3 OVATION 3 trial of IMNN-001 is exceeding expectations, running at approximately 0.5 patients per site per month compared to the planned 0.3. This accelerated pace is driven by promising survival data from the Phase 2 OVATION 2 study and a strong safety profile, with enrollment now projected to complete in Q2 2029.
Key figures
- Drug Name
- IMNN-001
- Phase Of Trial
- Phase 3
- Dosage
- 100 mg/m²
- Enrollment rate
- 0.5
- Ovation 2 patients
- 112
- Planned enrollment rate
- 0.3
- Historical industry rate
- 0.2
- Enrollment completion qtr
- Q2 2029
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.